Evaluation of a saliva molecular point of care for the detection of SARS-CoV-2 in ambulatory care

Sci Rep. 2021 Oct 26;11(1):21126. doi: 10.1038/s41598-021-00560-8.

Abstract

Rapid identification of SARS-CoV-2-infected individuals is a cornerstone for the control of virus spread. The sensitivity of SARS-CoV-2 RNA detection by RT-PCR is similar in saliva and nasopharyngeal swabs. Rapid molecular point-of-care tests in saliva could facilitate, broaden and speed up the diagnosis. We conducted a prospective study in two community COVID-19 screening centers to evaluate the performances of a CE-marked RT-LAMP assay (EasyCoV) designed for the detection of SARS-CoV2 RNA from fresh saliva samples, compared to nasopharyngeal RT-PCR, to saliva RT-PCR and to nasopharyngeal antigen testing. Overall, 117 of the 1718 participants (7%) tested positive with nasopharyngeal RT-PCR. Compared to nasopharyngeal RT-PCR, the sensitivity and specificity of the RT-LAMP assay in saliva were 34% and 97%, respectively. The Ct values of nasopharyngeal RT-PCR were significantly lower in the 40 true positive subjects with saliva RT-LAMP (Ct 25.9) than in the 48 false negative subjects with saliva RT-LAMP (Ct 28.4) (p = 0.028). Considering six alternate criteria for reference tests, including saliva RT-PCR and nasopharyngeal antigen, the sensitivity of saliva RT-LAMP ranged between 27 and 44%. The detection of SARS-CoV-2 in crude saliva samples with an RT-LAMP assay had a lower sensitivity than nasopharyngeal RT-PCR, saliva RT-PCR and nasopharyngeal antigen testing.Registration number: NCT04578509.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Ambulatory Care / methods*
  • COVID-19 / diagnosis*
  • COVID-19 / metabolism*
  • COVID-19 Nucleic Acid Testing / methods*
  • Diagnostic Tests, Routine
  • False Negative Reactions
  • False Positive Reactions
  • Female
  • Humans
  • Male
  • Middle Aged
  • Molecular Diagnostic Techniques
  • Molecular Medicine
  • Nasopharynx / virology
  • Nucleic Acid Amplification Techniques
  • Point-of-Care Systems
  • Point-of-Care Testing
  • Prospective Studies
  • RNA, Viral / genetics
  • Real-Time Polymerase Chain Reaction
  • Reproducibility of Results
  • SARS-CoV-2*
  • Saliva / metabolism*
  • Sensitivity and Specificity

Substances

  • RNA, Viral

Supplementary concepts

  • LAMP assay

Associated data

  • ClinicalTrials.gov/NCT04578509